Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs

Osivax Announces Vaccination of Last Patient in Phase 2a Clinical Trial Evaluating OVX836 Combined with QIVs  478 participants were enrolled across Australia  Full immunogenicity and safety results expected in the second half of 2024 Lyon, France – March 26, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses, today announced that …

Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033

Osivax Announces Vaccination of First Participant in First-in-Human Trial Evaluating Sarbecovirus Vaccine Candidate OVX033 Phase 1 study to evaluate safety and immunogenicity of sarbecovirus (coronavirus) vaccine candidate, OVX033, at ascending dose levels  The trial will enroll 48 participants in France Lyon, France – February 15, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against …

Osivax Appoints Dr. Nicola Groth as Chief Medical Officer

Osivax  Appoints Dr. Nicola Groth as Chief Medical Officer Lyon, France – January 25, 2024 – Osivax, a biopharmaceutical company developing vaccines to provide broad-spectrum protection against highly mutating infectious viruses and diseases, announced today the appointment of Dr. Nicola Groth, MD, PhD to its executive committee as Chief Medical Officer. She brings over 25 years of experience …

Osivax Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836

Osivax  Receives Over USD 1.5M Grant from NIAID to Advance Development of Broad-Spectrum Influenza Vaccine Candidate, OVX836 Grant to support preclinical evaluation of OVX836 in providing protection against pandemic influenza strains  OVX836 has already been evaluated in several Phase 2 clinical trials against seasonal influenza with initial signals of broad-spectrum protection Lyon, France – December 5, 2023 …